Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

76.00
Delayed Data
As of 3:59pm ET
 +0.43 / +0.57%
Today’s Change
49.96
Today|||52-Week Range
110.75
-19.27%
Year-to-Date

Today’s Trading

Previous close75.57
Today’s open77.25
Day’s range75.25 - 77.25
Volume382,362
Average volume (3 months)794,857
Market cap$6.5B
Dividend yield--
Data as of 3:59pm ET, 09/26/2016

Growth & Valuation

Earnings growth (last year)+28.87%
Earnings growth (this year)-37.37%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)-18.72%
P/E ratioNM
Price/Sales192.40
Price/Book5.08

Competitors

 Today’s
change
Today’s
% change
OPKOPKO Health Inc-0.03-0.27%
TSROTESARO Inc-0.77-0.71%
UTHRUnited Therapeutics ...-1.64-1.29%
ALKSAlkermes Plc-1.00-2.02%
Data as of 3:59pm ET, 09/26/2016

Financials

Next reporting dateNovember 2, 2016
EPS forecast (this quarter)-$1.15
Annual revenue (last year)$41.1M
Annual profit (last year)-$290.1M
Net profit margin-705.83%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John M. Maraganore
President
Barry E. Greene
Corporate headquarters
Cambridge, Massachusetts

Forecasts

Search for Jobs